Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges

Future Med Chem. 2024 Dec 23:1-5. doi: 10.1080/17568919.2024.2444865. Online ahead of print.

Xin Yang¹, Xiang Li², Yue-Lin Zhang², Sheng-Nan Zhang¹, Miao Zhang¹, Chong Sun¹, Li Yang², Hong-Min Liu^{1

3}, Shuo Yuan^{1

3}

¹ Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
² Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
³ School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Zhengzhou University, Zhengzhou, China.

No abstract available

Keywords: KRAS inhibitor; anti-cancer; combination therapy; drug design; drug resistance.

Publication types